KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Acquisitions (2020 - 2025)

GoodRx Holdings' Acquisitions history spans 4 years, with the latest figure at $13.4 million for Q4 2025.

  • For Q4 2025, Acquisitions changed N/A year-over-year to $13.4 million; the TTM value through Dec 2025 reached $43.4 million, changed N/A, while the annual FY2025 figure was $43.4 million, N/A changed from the prior year.
  • Acquisitions for Q4 2025 was $13.4 million at GoodRx Holdings, down from $30.0 million in the prior quarter.
  • Across five years, Acquisitions topped out at $149.9 million in Q2 2022 and bottomed at $7.0 million in Q1 2022.
  • The 3-year median for Acquisitions is $22.3 million (2021), against an average of $56.8 million.
  • The largest annual shift saw Acquisitions tumbled 73.94% in 2021 before it grew 19.21% in 2022.
  • A 3-year view of Acquisitions shows it stood at $14.5 million in 2021, then surged by 930.79% to $149.9 million in 2022, then plummeted by 91.03% to $13.4 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Acquisitions are $13.4 million (Q4 2025), $30.0 million (Q1 2025), and $149.9 million (Q2 2022).